← All trials
NCT01681563
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Sep 1, 2011
- Primary completion
- Nov 1, 2015
- Completion date
- Dec 1, 2016
- First posted
- —
- Last posted
- —
- Enrollment
- 47
- Arms / groups
- 1 / —
- Source
- AACT · pre-existing
Sponsors
- University of MilanLead sponsor
- Istituti Ospitalieri di CremonaOverall official - principal investigator
- Azienda Ospedaliera Ospedale Civile di LegnanoOverall official - principal investigator
- Vita-Salute University of Milano. ItalyOverall official - principal investigator
- ASL della provinciaOverall official - principal investigator
- Ospedale Valduce, ComoOverall official - principal investigator
- University of BresciaOverall official - principal investigator
- Presidio Ospedaliero Spedali Civili di BresciaOverall official - principal investigator
- Regione LombardiaCollaborator
- GlaxoSmithKlineCollaborator
- PfizerCollaborator
- Azienda Ospedaliera San Gerardo di MonzaOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.